病毒学
血清转化
重组DNA
接种疫苗
效力
医学
dna疫苗
乙肝疫苗
效价
免疫原性
免疫
乙型肝炎病毒
免疫学
生物
抗体
乙型肝炎表面抗原
病毒
遗传学
体外
基因
作者
M Piazza,N Abrescia,L Picciotto,R. Orlando,Raimondo Cerini,Guglielmo Borgia,M Cotugno
出处
期刊:PubMed
日期:1993-04-01
卷期号:69 (4): 273-80
被引量:7
摘要
A vaccination cycle cannot always be completed with the same type of vaccine with which it was initiated because the same type of vaccine is not always available at the vaccination centers. For this reason we have verified the possibility of substituting one of two anti hepatitis B DNA-recombinant vaccines [Engerix B (SK&F); Recombivax HB (MSD)] both available in Italy in the vaccination protocol. A study was performed on 480 subjects using both types of DNA recombinant vaccine and on 160 using only one type of vaccine. Our data show that there is no difference in immunogenic potency of the two DNA recombinant vaccines available in Italy and that a cycle begun with one vaccine can be completed with the other with no effect on the percentage of seroconversion or the mean anti-HBs titre.
科研通智能强力驱动
Strongly Powered by AbleSci AI